BOSTON — A Dedham veterinarian has agreed to investigate allegations that he maintained inadequate records of controlled substances, improperly stocked controlled substances at his office and home, ordered controlled substances without a Drug Enforcement Administration (DEA) registration, and failed to report that he on parole was on his DEA registration forms.
Wilbur M. Salter, II DVM, a veterinarian who practices at Animed Pet Hospital in Dedham, has agreed to pay $15,000 to resolve allegations that he violated the Controlled Substances Act (CSA) civil remedies provisions have. Enacted to prevent the diversion or misuse of controlled substances, the CSA requires complete and accurate records by healthcare professionals – including veterinarians – and others involved in the distribution and administration of controlled substances.
Pursuant to the settlement agreement, Dr. Salter acknowledged that he failed to provide required records relating to Euthanasia Solution, Ketamine, Diazepam 5mg, Hydrocodone Fluid and Diazepam 1mg in connection with a 2019 DEA audit of controlled substances at his practice. As a result, investigators found CSA violations related to these controlled substances. dr Salter also admitted that he stockpiled controlled substances at his place of residence but did not register his place of residence with the DEA; improperly stored tramadol, a controlled substance, in an unlocked cupboard; ordered a Schedule IV controlled substance after losing his DEA registration; and did not report that the Board of Registration in Veterinary Medicine had placed him on probation as required on his subsequent DEA registration forms.
“It’s important that all prescribers — including veterinarians — maintain accurate controlled substance records so we can identify and prevent any diversion, especially amid a rampant and destructive opioid epidemic,” said US Attorney Rachael S. Rollins. “We will enforce compliance with these important safety precautions.”
“The DEA is committed to ensuring that all registrants comply with the necessary regulations enforceable by the Controlled Substances Act,” said Brian D. Boyle, DEA’s Special Agent in Charge, Boston Division. “Failure to do so increases the potential for distraction and puts public health and safety at risk. DEA is committed to working with our law enforcement and regulatory partners to ensure these rules and regulations are followed.”
During the examination, Dr. Salter revealed his DEA registration number and, as part of the settlement, agreed that he would not apply for a new DEA registration number.
US Attorney Rollins and DEA SAC Boyle made the announcement today. Assistant US Attorney Carol E., chief of Rollins’ civil division, handled the case.